The position In this vital role, you will be responsible for identifying and maturing novel treatment options for Type 2 Diabetes and related comorbidities. As such, you will work with stakeholders across the organisation on everything from target ID campaigns to maturing new targets for portfolio entry and ultimately to move projects across the value chain. Key responsibilities will include: · Developing a profound understanding of the pathogenic mechanisms underlying beta cell decline. · Project execution with focus on running experiments in relevant human in vitro systems for exploration of Mechanism of Action (MoA) as well as application of translational tools. · Taking active part in evaluation of external opportunities from academia, biotech, and pharma. · Keeping up to speed on new technological advancements. You are expected to spend 30-40% of your time in the lab. Qualifications You hold a PhD within cellular or molecular biology (or similar) with at least 5-7 years of post-graduate experience, part of which is drug discovery experience from pharma, biotech, or academia. You have profound experience and in-depth knowledge of pancreatic islet biology in the context of type 2 diabetes as well as drug discovery with the ability/experience to move novel drug targets from concepts to established projects The ideal candidate has: · Experience with functional islet studies, including measurements of hormone secretion. · Documented expertise in cellular signalling. · Preferably experience in measurement of intracellular [Ca2+] mobilization and single cell RNA sequencing. · Fluorescence microscopy and fluorescence-activated cell sorting. · Strong international scientific network. · The ability to set scientific direction within area of expertise and influence stakeholders in a large matrix organisation. On a personal level, you are collaborative, team player, highly motivated and driven with ability to thrive in a fast-paced innovative research environment. About the department The department is anchored in the Diabetes and Obesity research area within Global Drug Discovery (GDD), Novo Nordisk A/S. As part of Novo Nordisk’s strategy within chronic metabolic diseases, we are focusing on target identification, target validation and pre-clinical characterisation of new assets to become novel treatment options for people living with cardiometabolic diseases. In close collaboration with our colleagues across GDD, we are working in an organ-centric and disease agnostic manner to develop, characterise and utilize in vitro tools to elucidate mode-of-action and profiling of novel biology and molecules for early evaluation of drug candidates. Working at Novo Nordisk Novo Nordisk is its people. We know that life is anything but linear and balancing what is important at different stages of our career is never easy. That’s why we make room for diverse life situations, always putting people first. We value our employees for the unique skills they bring to the table, and we work continuously to bring out the best in them. Working at Novo Nordisk is working toward something bigger than ourselves, and it’s a collective effort. Novo Nordisk relies on the joint potential and collaboration of its more than 40, employees. Together, we go further. Together, we’re life changing.